GSK’s outgoing chief executive, Emma Walmsley, has said Britain will struggle to be a “life sciences superpower” unless it overhauls drug pricing.
As ministers draw up proposals to increase the amount the NHS spends on new medicines by up to 25%, Walmsley said she was “hopeful and ambitious” that the standoff with the pharma industry could be resolved.
